{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:00:47Z","timestamp":1762506047003,"version":"3.41.2"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/igc.0b013e31828566f1","type":"journal-article","created":{"date-parts":[[2013,2,2]],"date-time":"2013-02-02T04:45:07Z","timestamp":1359780307000},"page":"533-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Alberto A.","family":"Mendivil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Micha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"John V.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Rettenmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa N.","family":"Abaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina L.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram H.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e31828566f1_bb0005","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0010","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"du Bois","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0015","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ygyno.2004.05.050","article-title":"Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer","volume":"94","author":"Micha","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0020","first-page":"539","article-title":"Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status","volume":"24","author":"Chobanian","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ygyno.2009.09.039","article-title":"Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines","volume":"116","author":"Dietrich","year":"2010","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0030","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2407-6-183","article-title":"Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients","volume":"6","author":"Sonnemann","year":"2006","journal-title":"BMC Cancer."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0035","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","article-title":"Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"125","author":"Zhang","year":"2005","journal-title":"J Invest Dermatol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"Sill M, Hoffman JS, et al; Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"109","author":"Modesitt","year":"2008","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0050","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2006.09.011","article-title":"In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer","volume":"104","author":"Cooper","year":"2007","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0055","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ygyno.2007.10.022","article-title":"The effect of maximal surgical cytoreduction on sensitivity to platinum- taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer","volume":"108","author":"Eisenhauer","year":"2008","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0060","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/gyno.1997.4916","article-title":"Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer","volume":"68","author":"Brown","year":"1998","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U","article-title":"Paclitaxel administered by 1-hour infusion","volume":"74","author":"Hainsworth","year":"1994","journal-title":"Cancer."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0070","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0075","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-79-4-604","article-title":"Creatinine clearance: bedside estimate","volume":"79","author":"Jelliffe","year":"1973","journal-title":"Ann Intern Med."},{"year":"2010","series-title":"National Cancer Institute: Common Terminology Criteria for Adverse Events (version 4.03)","key":"10.1097\/IGC.0b013e31828566f1_bb0080"},{"key":"10.1097\/IGC.0b013e31828566f1_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0090","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-03-0787","article-title":"Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer","volume":"10","author":"Rustin","year":"2004","journal-title":"Clin Cancer Res."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e31828566f1_or0005","unstructured":"Pan LN, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol."},{"key":"10.1097\/IGC.0b013e31828566f1_or0010","unstructured":"2007;4:337-343."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2009.01.002","article-title":"Development of vorinostat: current applications and future perspectives for cancer therapy","volume":"280","author":"Richon","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0110","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0090-8258(03)00472-4","article-title":"First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer","volume":"90","author":"Stuart","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0115","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0090-8258(03)00128-8","article-title":"First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients","volume":"89","author":"Romanini","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1525-1438.2007.00886.x","article-title":"A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer","volume":"17","author":"Micha","year":"2007","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejso.2008.01.005","article-title":"Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients","volume":"35","author":"Colombo","year":"2009","journal-title":"Eur J Surg Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.hoc.2011.10.004","article-title":"Current surgical management of ovarian cancer","volume":"26","author":"Schorge","year":"2012","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0135","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/IGC.0b013e3181e94331","article-title":"A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma","volume":"20","author":"Brown","year":"2010","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0140","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1006\/gyno.1995.1140","article-title":"Intestinal perforation secondary to paclitaxel","volume":"57","author":"Rose","year":"1995","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0145","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1447-0756.2010.01223.x","article-title":"Comparison of the efficacy between paclitaxel\/carboplatin and doxorubicin\/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience","volume":"36","author":"Kim","year":"2010","journal-title":"J Obstet Gynaecol Res."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0150","first-page":"541","article-title":"Colonic perforation secondary to taxol therapy: an unusual presentation","volume":"29","author":"de Haan","year":"2006","journal-title":"Onkologie."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0155","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clbc.2011.04.002","article-title":"Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer","volume":"11","author":"Yardley","year":"2011","journal-title":"Clin Breast Cancer."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1755-8794-2-67","article-title":"DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines","volume":"2","author":"LaBonte","year":"2009","journal-title":"BMC Med Genomics."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0165","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s10147-011-0249-8","article-title":"Ileal perforation induced by acute radiation injury under gefitinib treatment","volume":"16","author":"Muraoka","year":"2011","journal-title":"Int J Clin Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0170","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/jcp.22574","article-title":"HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT","volume":"226","author":"Bruzzese","year":"2011","journal-title":"J Cell Physiol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0175","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1158\/1078-0432.CCR-05-2404","article-title":"Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells","volume":"12","author":"Erjala","year":"2006","journal-title":"Clin Cancer Res."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0180","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/en.2006-0896","article-title":"Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin","volume":"148","author":"Uchida","year":"2007","journal-title":"Endocrinology."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0185","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21969","article-title":"Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis","volume":"107","author":"Wright","year":"2006","journal-title":"Cancer."},{"key":"10.1097\/IGC.0b013e31828566f1_bb0195","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2007.06.004","article-title":"Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening","volume":"107","author":"Simpkins","year":"2007","journal-title":"Gynecol Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24019042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24019042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e31828566f1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:29:54Z","timestamp":1753223394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24019042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1048891X24019042"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e31828566f1","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased Incidence of Severe Gastrointestinal Events With First-Line Paclitaxel, Carboplatin, and Vorinostat Chemotherapy for Advanced-Stage Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e31828566f1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2013 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}